Literature DB >> 2434442

Increased therapeutic efficacy of cis-platinum complexes of poly-L-glutamic acid against a murine carcinoma.

B Schechter, M Wilchek, R Arnon.   

Abstract

Cis-diamminedichloroplatinum(II) (cis-DDP) and cis diamminediaquoplatinum(II) nitrate (cis-aq) were complexed to poly-L-glutamic acid (PG) of Mr 13,000 or 58,000. Soluble complexes were formed by mixing the platinum(II) compounds with the PG preparations in water at a molar ratio of one platinum(II) to 5 glutamyl residues of the PG. Compared to free cis-DDP, the complexes were about 2 to 6 times less cytotoxic to F9 embryonal carcinoma cells in vitro. In vivo studies with this tumor indicated that when administered i.p. one day after the tumor cells, the complexes were somewhat less active than cis-DDP. However, in comparison to the free drug which, due to its toxicity, was effective only within a very narrow dose range, the complexes were much less toxic, manifesting a wide therapeutic range in which no mortality occurred either from the tumor or as a result of the toxic effects of the drug. Cis-DDP and cis-aq complexes of PG Mr-58,000 were somewhat more toxic than the complexes of PG Mr, 13,000. The in vivo anti-tumor activity of most complexes was superior to that of free cis-DDP when tested in mice carrying high tumor loads. Due to their wide therapeutic range, the complexes could be given at high drug doses resulting in increased life span of the tumor-bearing mice. Moreover, 3 repeated injections of these high doses did not cause death from toxicity and resulted in partial or total eradication of advanced tumors.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2434442     DOI: 10.1002/ijc.2910390323

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  3 in total

1.  Selective cytotoxicity against tumor cells by cisplatin complexed to antitumor antibodies via carboxymethyl dextran.

Authors:  B Schechter; R Pauzner; R Arnon; J Haimovich; M Wilchek
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

2.  Blood levels and serum protein binding of cis-platinum(II) complexed to carboxymethyl-dextran.

Authors:  B Schechter; M A Rosing; M Wilchek; R Arnon
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 3.  Metal-based antibody drug conjugates. Potential and challenges in their application as targeted therapies in cancer.

Authors:  Virginia Del Solar; María Contel
Journal:  J Inorg Biochem       Date:  2019-07-18       Impact factor: 4.155

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.